breast cancer

For breast cancer patient Erin Hatcher, participating in a research study to learn about the potential for heart-related side effects of chemotherapy is a “win-win” situation to protect her health in the future.

DCI investigators are invited to attend the Inaugural Metastatic Breast Cancer Collaborative Research Virtual Summit.

Susan Dent, MD, co-director of the Duke Cardio-Oncology Program, is a leading international expert in the field. She is also associate director of Clinical Research in DCI's Breast Program.

In an open letter, the NCCN, ACS, and major U.S. cancer centers, inc. DCI, urge public to resume cancer screening & treatment during pandemic.

Qualifying patients get access to blood draws at home or at a nearby lab and the services of a nurse coach for symptom management & emotional support.

The journey of a new drug for advanced breast cancer.

Breast cancer survivor Katrina Cooke has become a professional speaker, peer mentor, and advocate.

The NAI recognizes academic inventors for their spirit of innovation in creating or facilitating outstanding inventions that have made a tangible impact on the quality of life, economic development and welfare of society. 

You can count on one hand the number of times a young graduate student finds a drug, then the drug is patented, licensed, and in a phase 2 trial within a couple years.

The American Cancer Society has a long history of awarding grants to DCI researchers as they work to better understand the complexities of cancer and develop new treatments.

Carey Anders, MD, and immunology researchers Erika Crosby, PhD, Zachary Hartman, PhD, among featured speakers at the national Komen MBC webinar series.

A Duke mammographer shares her breast cancer story.

Komen scholar Donald McDonnell, PhD, spoke about the importance of investing in breast cancer research at MBC gala that raised $150K.

ACS hosted its first North Carolina Breast Health Equity Summit. Lola Fayanju, MD, MA, MPHS, gave the "State of the State" address. Watch the recording.

October is Breast Cancer Awareness Month. As with all types of cancer, early detection is the best defense against this disease that will affect about 1 in 8 women in the U.S.

Katrina Cooke has beaten the odds; surviving nearly nine years with metastatic breast cancer. Giving of her time to make things better for others has been her lifeline.

DCI faculty Michaela Dinan, PhD, on the impact of the Oncotype DX test on HR+ breast cancer patients over 65, treatment disparities, & the latest therapies.

For the 19th year, DCI was local presenting sponsor for Komen NCTC's Triangle Race for the Cure, held Sept. 12. Team DCI raised spirits and funds.

Join Team DCI and turn your miles walked into dollars raised throughout the month of October, then join the virtual National Celebration on October 18.

Komen NCTC hosts its first annual gala to support metastatic breast cancer research; a virtual event with speakers, auctions, and treats on Saturday, October 10, at 7 p.m.

Duke Cancer Institute welcomes a new medical oncologist specializing in the treatment of breast cancer. He will practice at two of DCI's Wake County locations.

A new approach to training computational models on biological processes provides insights into how and why cancer cells metastasize to certain areas of the vasculature.

The Komen Triangle Race for the Cure on Saturday, September 12, is now virtual. Susan Dent, MD, FRCPC, MD, and Sarah Sammons, MD, are DCI's honorary team captains.

A vaccine for HER2-positive breast cancers that is being tested in a clinical trial at DCI is part of an effective, two-drug strategy for enlisting the immune system to fight tumors.

On June 9, DCI and Susan G. Komen Triangle to Coast hosted "Navigating Survivorship,"a live patient forum on breast cancer and survivorship.

Carey Anders, MD, who completed a residency and fellowship at Duke, rounds out the leadership team at the Duke Center for Brain and Spine Metastasis

Lola Fayanju, MD, MA, MPHS, is determined to understand all of her patients as people.

Dr. Fayanju talks about some of the disparities we see in breast cancer, as well as some ways to ease stress and despair in these challenging times.

Flags were lowered to half-staff today across Duke for Neil Spector, MD, physician-scientist, mentor, advocate, friend, husband, and father who passed away on June 14.

Duke University School of Medicine podcast "HeadScratchers" features Kelly Marcom, MD.

"It's my comfort spot. I can live my life when I’m here, even if I’m not feeling well, and they are always here to take care of me.”

If mothers, sisters and daughters have a history of breast and ovarian cancers, a man's risk for prostate cancer is also significantly increased.

The nine-woman APP team was awarded for their exceptional service to the Duke community during the 2018-2019 academic year.

Genetic testing at Duke revealed a devastating diagnosis for a young nurse. But she feels it also may have saved her life.

Duke Fencing students are asking the community to Fence4TheFight against breast cancer, in honor of their long-time manager Elizabeth Beguinet.

Dorothy Sipkins, MD, PhD, and P. Kelly Marcom, MD, are co-PIs on a Phase 1 clinical trial of a new drug for breast cancer patients whose disease has spread to the bone.

DCI was invited to join the elite international AACR Project GENIE consortium, whose registry contains clinical-grade cancer genomic sequencing data from nearly 71,000 patients & 80 major cancer types.

Jennifer K. Plichta, MD, Assistant Professor of Surgery, Division of Surgical Oncology, on being appointed to the editorial board of Breast Cancer Research.

Lola Fayanju, MD, and her team will develop a prediction model to identify women with mutable risk factors for compromised breast cancer care.

Updated genetic screening guidelines published by NCCN feature emerging evidence on personalized medicine.

ICYMI the AACI's Physician Clinical Leadership Initiative (PCLI) presented a two-part webinar series on hereditary cancer programs and cancer risk assessment.

The mainstay drug trastuzumab could benefit from another antibody to remove roadblocks.

Duke Cancer Institute hosted its Sixth Annual Scientific Retreat on Friday, October 25; attracting 166 DCI physicians, researchers, staff, and guests.

What if beating breast cancer means weakening what beats in the chest?

Drug shuts down a pathway tumor cells use to become resistant to hormone therapies in animal studies.

Randles' team is one of 15 investigator-led teams being given priority to run her cancer simulations on the nation's first exascale computer "Aurora."

For a sixth year, Duke Cancer Institute is teaming up in October with the American Cancer Society (ACS) as local presenting sponsor for Making Strides.

What's Best For Breasts?, A Conversation with Duke Clinicians, will be held at the Trent Semans Center Grand Hall from 8 a.m. to 3 p.m. on Saturday, Sept. 21.